TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD)

CUSIP: 88338N206

Q1 2026 13F Holders as of 31 Mar 2026

Holder snapshot 6 signals
Share change
+520,174
SEC-reported price per share
$2.02
Indexed holders
47
Value change
+$1,050,571
Number of buys
14
Number of sells
12
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
11,627,985

Security key

88338N206

Report period

Q1 2026

Indexed institutions

47

Top holders

10

Ownership snapshot

Top reported holders of TXMD - TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Clearline Capital LP
Disclosed value leader
John C.k. Milligan IV
Comparable rows
1/15
Latest evidence
31 Dec 2025
13F 13D/G 3/4/5 Lead comparable stake: 5.5% 14 rows are not safely comparable across share classes. 13D/G row: Clearline Capital LP Showing 1-6 of 15 holder rows.

Quick read

Clearline Capital LP leads the comparable SEC ownership view at 5.5%.

1 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Clearline Capital LP's linked filing trail.
Comparable ownership Top 1
Clearline Capital LP 5.5%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Clearline Capital LP
13F 13D/G
Company
5.5%
Reported 13D/G · 31 Dec 2024
$1,035,412
635,222 shares
— 31 Dec 2025
Rubric Capital Management LP
3/4/5 13F
Director, Other*, 10%+ Owner · Company
—
denominator unverified
$6,718,950
2,946,908 shares
— 15 Nov 2023
John C.k. Milligan IV
3/4/5
Secretary/CEO of subsidiary
—
mixed-class rows
$12,698,322
5,542,076 shares
mixed-class rows
— 10 May 2021
Hugh O'Dowd
3/4/5
Chief Executive Officer
—
mixed-class rows
$11,415,713
4,250,000 shares
mixed-class rows
— 31 Mar 2022
Robert G. Finizio
3/4/5
CEO, Director
—
mixed-class rows
$5,305,888
2,240,000 shares
mixed-class rows
— 01 Jul 2021
James Darecca
3/4/5
Chief Financial Officer
—
mixed-class rows
$1,857,402
558,163 shares
mixed-class rows
— 10 Aug 2021
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
47
Shares
3,930,452
Indexed holders
47
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q1 2026 vs Q4 2025 Across Filers

Q4 2025 indexed holders
41
Q1 2026 indexed holders
47
Indexed holder difference
6
Investor Q4 2025 Shares Q1 2026 Shares Share Diff Share Chg % Q4 2025 value Q1 2026 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .